georgie18
4 years ago
KTOV...$4.15...in the P/M...TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the βCompanyβ) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has changed its corporate name from Kitov Pharma Ltd. to Purple Biotech Ltd. The name change will be effective for trading purposes on the Tel Aviv Stock Exchange (TASE) and the NASDAQ Capital Market (NASDAQ) as of market open on December 22, 2020. At that time, the Companyβs ordinary shares and American Depositary Shares (ADSs) will begin to trade under the new ticker symbol, βPPBT,β on the TASE and NASDAQ, respectively. The Companyβs ordinary shares will continue to trade on the TASE and its ADSs will continue to trade on NASDAQ under the ticker symbol βKTOVβ through market close on December 21, 2020. The Companyβs ADSs were assigned a new CUSIP number (74638P109), effective on December 22, 2020, as described above.
georgie18
4 years ago
KTOV...$4.50...in the P/M...https://www.otcmarkets.com/stock/KTOV/news/story?e&id=1716514
TEL AVIV, Israel, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (βKitovβ) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced new data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3 is being presented in a video recorded presentation at the Epigenetics and Metabolism AACR Special Virtual Conference by researchers at Tel-Aviv University. The data was generated as part of the Companyβs collaboration with Professor Ido Wolf, Head of the Oncology Division, Tel Aviv Sourasky Medical Center.